PRIMERS IN CARDIO-ONCOLOGY
Cardiovascular Safety in Oncology Clinical Trials
JACC: CardioOncology Primer
CSRC Continues To Drive Impact
Check out our latest paper 'Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOnCology Primer" and get guidance how:
- Improved cardiovascular event definitions should be used in cancer therapy trials
- Refinements in safety data ascertainment methods should allow better characterization of potential treatment-associated toxicities
- Optimal cardiovascular event ascertainment and recording methods may very depending on the drug, development stage, and patient factors